Latest Litigation Risk News

FleetPartners has reached an in-principle $27 million settlement to resolve a shareholder class action related to disclosures from 2017 to 2019, with the cost fully covered by insurance and no admission of liability.

Light & Wonder (ASX:LNW) posted modest revenue growth in 2025, driven by Gaming and iGaming segments, while SciPlay revenue dipped slightly. The company completed its Grover acquisition, settled a $128 million IP dispute with Aristocrat, and transitioned to a sole ASX listing.

Light & Wonder has been hit with a class action lawsuit in Victoria alleging misleading statements about its Dragon Train game, targeting shareholders who bought Chess Depositary Interests between May 2023 and September 2024. The company has pledged a vigorous defence amid ongoing legal challenges.

Transurban Group has reported a robust turnaround in its half-year results to December 2025, with revenue rising 8.1% and profit rebounding from a loss to $343 million. Major infrastructure projects like Melbourne’s West Gate Tunnel and Sydney’s M7-M12 integration are driving growth and operational momentum.

WIN Metals Ltd has launched a prospectus offering up to 78.57 million free attaching options to recent placement participants and its Executive Chairman, aiming to remove trading restrictions and enable market liquidity. The offer follows a $5.5 million capital raise and comes amid ongoing litigation risks.

Ovanti Limited advances its U.S. buy now, pay later ambitions through strategic partnerships and a proposed Nasdaq listing valued at US$300 million.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

Acusensus Limited has announced a $30 million equity placement to bolster its balance sheet, alongside winning a landmark $34 million contract in Connecticut, marking a significant step in its US expansion. The company also reported multiple contract expansions in Australia and a new debt facility to support its growth ambitions.

Acusensus Limited has successfully raised $30 million through a placement of 20 million shares at $1.50 each, supported by both existing and new investors. The capital injection aims to fuel business development, product innovation, and operational expansion.

Lifestyle Communities is extending an option for existing homeowners to adopt a revised Deferred Management Fee model following a pivotal VCAT ruling, aiming to enhance transparency and goodwill regardless of the appeal outcome.

Identitii Limited has announced a pro rata non-renounceable rights issue to raise approximately $2.88 million, partially underwritten by Beauvais Capital Pty Ltd. The funds will support the development and commercialisation of its BNDRY platform amid ongoing patent litigation risks.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.